Filana Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

Filana Therapeutics, Inc. has insufficient data to evaluate this check.

Filana Therapeutics, Inc. has insufficient data to evaluate this check.

Filana Therapeutics, Inc. has insufficient data to evaluate this check.

Filana Therapeutics, Inc. has a net cash position, so leverage is healthy.

Filana Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Filana Therapeutics, Inc. has insufficient data to evaluate this check.

Filana Therapeutics, Inc. has insufficient data to evaluate this check.

Filana Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Filana Therapeutics, Inc.'s return on equity of -58.78%, is lower than 15.00%, indicating bad performance

Filana Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Filana Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Filana Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Filana Therapeutics, Inc. has negative free cash flow, indicating cash burn

Filana Therapeutics, Inc.'s yearly earnings has decreased 273.73% since last year from $-24.34M to $-90.97M, signaling decreasing performance

Filana Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -72.12% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Filana Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Filana Therapeutics, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Filana Therapeutics, Inc. has insufficient net-income and equity history to evaluate ROE consistency.

Filana Therapeutics, Inc. has insufficient data to evaluate this check.

Filana Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Filana Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Filana Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Filana Therapeutics, Inc. has insufficient data to evaluate this check.

Filana Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Filana Therapeutics, Inc. has a price-to-book ratio of 0.76x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Filana Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue